Tackling the Opioid Epidemic

Treating Women with Opioid Use Disorders: A Focus on Pregnant and Parenting Women

Activity Details
  • Credit Amounts:
    • CME: 0.00
    • CNE: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Jan 24, 2017
  • Expires: Jan 24, 2020
  • System Requirements:
  • Average User Rating:
    (6 Ratings)

Faculty

Hendree' Jones Hendree' Jones, PhD
Professor, Obstetrics and Gynecology
University of North Carolina School of Medicine
Adjunct Professor, Psychology and Neuroscience
Johns Hopkins University School of Medicine
Executive Director, Horizons
Chapel Hill, North Carolina

Needs Statement

Drug overdose is a huge problem facing the health care system in Kentucky. Drug overdose deaths are acute poisoning deaths due to prescription or illicit drugs. According to data from the National Center for Health Statistics, Kentucky had the 2nd highest drug overdose death rate in the US in 2013.

KENTUCKY INJURY PREVENTION AND RESEARCH CENTER http://www.mc.uky.edu/kiprc/
KENTUCKY DEPARTMENT FOR PUBLIC HEALTH http://chfs.ky.gov/dph/
Released October 2015

As of 2012, 5.9% of pregnant women in US report illicit drug use.1 Opioid use during pregnancy ranges from 1-21 % nationally.2 1.6% of pregnant women meet criteria for drug use disorder.3 Neonatal Abstinence Syndrome (NAS) increased 300% from 2000 – 2009.

1National Survey of Drug Use and Health, SAMHSA, http://nsduh.rti.org
2Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am 012; 35(2): 441-60
3Vesga-Lopex O, Blanco C, Keyes K et al. Psychiatric disorders in pregnant and postpartum women in the United States. Arch gen Psych 2008; 65: 805-815
4Patrick S, Shumacher R, Bennyworth B. Neonatal Abstinence Syndrome and associated health care expenditures: United States, 2000 – 2009. J Am Med Assoc 2012; 307(18):E1

This activity has been approved by the KBML as meeting the statutory requirements of HB1.

Target Audience

Health care providers caring for pregnant women

Objectives

Upon completion of this education activity, participants will be able to:

  • Discuss considerations for women who have substance use problems
  • Explain nursing and integrated care surrounding opioid use disorders during pregnancy, the postpartum period, and neonatal abstinence syndrome

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and Kentucky Office of Drug Control Policy. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

This training has been approved by the KBML as meeting the statutory requirements of HB1.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Interpersonal and communication skills
  • Professionalism

CNE
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This educational activity is offered for a maximum of 1.00 ANCC contact hour.

The Kentucky Board of Nursing (KBN) approves The University of Kentucky, College of Nursing (UKCON) as a provider as well. ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of program content nor commercial sponsors. The University of Kentucky does not approve commercial products. This educational activity is offered for a maximum of 1.2 KBN contact hours.

Provider #: 3-0008-01-18- 883. In order to receive credit, participants complete this CNE activity and submit a credit application and evaluation form online. Certificates may be printed once the evaluation is completed.

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

Faculty Disclosure

Michelle Lofwalll, MD (planner) has relevant financial relationships with commercial interests as follows:

  • Braeburn Pharmaceuticals - Consultant and Principal Investigator - Consulting Fees and Research Contract
  • PCM Scientific - Speaker - Honoraria

No speaker or other planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Kentucky Office of Drug Control Policy.

In collaboration with Kentucky Injury Prevention and Research Center University of Kentucky College of Public Health.